AU2017317129B2 - Entacapone-related compounds to treat macular degeneration - Google Patents

Entacapone-related compounds to treat macular degeneration Download PDF

Info

Publication number
AU2017317129B2
AU2017317129B2 AU2017317129A AU2017317129A AU2017317129B2 AU 2017317129 B2 AU2017317129 B2 AU 2017317129B2 AU 2017317129 A AU2017317129 A AU 2017317129A AU 2017317129 A AU2017317129 A AU 2017317129A AU 2017317129 B2 AU2017317129 B2 AU 2017317129B2
Authority
AU
Australia
Prior art keywords
alkylene
alkyl
formulation
macular degeneration
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017317129A
Other languages
English (en)
Other versions
AU2017317129A1 (en
Inventor
Niu Huang
Shiming PENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Biological Sciences Beijin
Original Assignee
National Institute of Biological Sciences Beijin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Biological Sciences Beijin filed Critical National Institute of Biological Sciences Beijin
Publication of AU2017317129A1 publication Critical patent/AU2017317129A1/en
Application granted granted Critical
Publication of AU2017317129B2 publication Critical patent/AU2017317129B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017317129A 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration Active AU2017317129B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/096472 2016-08-24
CN2016096472 2016-08-24
PCT/CN2017/098575 WO2018036498A1 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Publications (2)

Publication Number Publication Date
AU2017317129A1 AU2017317129A1 (en) 2019-03-07
AU2017317129B2 true AU2017317129B2 (en) 2020-04-30

Family

ID=61245496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017317129A Active AU2017317129B2 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Country Status (7)

Country Link
US (1) US10980766B2 (https=)
EP (1) EP3503883B1 (https=)
JP (2) JP6898429B2 (https=)
CN (1) CN109689042B (https=)
AU (1) AU2017317129B2 (https=)
CA (1) CA3034547C (https=)
WO (1) WO2018036498A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
US20250074894A1 (en) * 2021-04-15 2025-03-06 Brown University Nitrophenyl-acrylamides and uses thereof
AU2023312773A1 (en) * 2022-07-29 2025-03-13 Rpxds Co., Ltd Fto inhibitors
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway
WO2025162358A1 (en) * 2024-01-30 2025-08-07 Rpxds Co., Ltd Fto inhibitors of bicyclic structures

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022140A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20100190851A1 (en) * 2007-01-17 2010-07-29 Remo Kranich Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI864875A0 (fi) 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200817315A (en) * 2006-06-16 2008-04-16 Sanol Arznei Schwarz Gmbh Entacapone-derivatives
EP1978014A1 (en) 2007-04-02 2008-10-08 Esteve Quimica, S.A. Process for the preparation of entacapone and intermediates thereof
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
WO2009129497A2 (en) * 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
EP2558103A4 (en) * 2010-04-12 2013-09-25 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
ES2858511T3 (es) * 2012-10-17 2021-09-30 Exonate Ltd Compuestos útiles para tratar neovascularización ocular
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
WO2015095257A2 (en) * 2013-12-18 2015-06-25 Emory University Managing visual dysfunction or loss of vision for diabetic subjects
WO2016123577A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
WO2016123576A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
EP3885337B1 (en) 2015-06-23 2025-01-15 National Institute Of Biological Sciences, Beijing Fto inhibitors
AU2017317129B2 (en) 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190851A1 (en) * 2007-01-17 2010-07-29 Remo Kranich Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions
WO2010022140A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONEKAWA, YOSHIHIRO et al., "Clinical Characteristics and Current Treatment of Age- Related Macular Degeneration", COLD SPRING HARB PERSPECTMED, (2014-10-03), vol. 5, no. 1, ISSN 2157-1422 *

Also Published As

Publication number Publication date
CN109689042A (zh) 2019-04-26
CA3034547A1 (en) 2018-03-01
US20190183842A1 (en) 2019-06-20
WO2018036498A1 (en) 2018-03-01
AU2017317129A1 (en) 2019-03-07
EP3503883B1 (en) 2022-05-04
JP2019526561A (ja) 2019-09-19
JP2021073265A (ja) 2021-05-13
CA3034547C (en) 2021-04-13
JP7116202B2 (ja) 2022-08-09
JP6898429B2 (ja) 2021-07-07
EP3503883A4 (en) 2020-04-15
US10980766B2 (en) 2021-04-20
EP3503883A1 (en) 2019-07-03
CN109689042B (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
AU2017317129B2 (en) Entacapone-related compounds to treat macular degeneration
WO2018036501A1 (en) Entacapone-related compounds to treat injury
EP1041982B1 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
CA3114208A1 (en) Inhibitors of vap-1
RU2496494C2 (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
WO2013009810A1 (en) Methods of treatment
WO2015118026A1 (en) Neurodegenerative therapies
EP3790540A1 (en) Methods for treating or limiting development of cardiovascular disease-related neurological disorders
CN101815514B (zh) 磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用
AU2013334860A1 (en) Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E
EA019194B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
KR102159164B1 (ko) 안질환용 치료제
JP7157769B2 (ja) 鎮痛剤化合物
JPWO2020023324A5 (https=)
US20140275169A1 (en) Combination Therapies for Enhancing Protein Degradation
TW201806601A (zh) σ受體配體在皰疹後遺疼痛中的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)